Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer.

54 The initial subgroup analysis found PFS estimates were more favourable for patients with brain metastases (HR 0.69, 95% CI 0.53-0.92), while the later updated analysis reported a nonsignificant trend for longer median intracranial PFS for patients in the lazertinib-amivantamab group compared with those in the osimertinib group (24.9 months versus 22.2 months, respectively; HR 0.82, 95% CI 0.82-1.09, nominal P = 0.165). 53 , 54 In a secondary analysis of biomarkers of high-risk disease, lazertin

also in 5,406 other papers